Roth MKM Maintains Buy on Cellectar Biosciences, Raises Price Target to $28
Portfolio Pulse from Benzinga Newsdesk
Roth MKM analyst Jonathan Aschoff has maintained a Buy rating on Cellectar Biosciences (NASDAQ:CLRB) and increased the price target from $20 to $28.
March 28, 2024 | 5:03 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Roth MKM analyst Jonathan Aschoff has reaffirmed a Buy rating on Cellectar Biosciences and raised the price target from $20 to $28.
The increase in price target by a reputable analyst suggests a strong confidence in Cellectar Biosciences' future performance. This endorsement is likely to positively influence investor sentiment and could lead to a short-term increase in the stock price.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100